CN107635988B - 抗真菌的苯甲酰胺类衍生物或其可药用盐 - Google Patents

抗真菌的苯甲酰胺类衍生物或其可药用盐 Download PDF

Info

Publication number
CN107635988B
CN107635988B CN201680028971.4A CN201680028971A CN107635988B CN 107635988 B CN107635988 B CN 107635988B CN 201680028971 A CN201680028971 A CN 201680028971A CN 107635988 B CN107635988 B CN 107635988B
Authority
CN
China
Prior art keywords
compound
formula
fungal
compounds
aspergillus fumigatus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680028971.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN107635988A (zh
Inventor
T·C·科利
伊藤和浩
P·斯特朗
须纳濑见广
M·麦康维尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pulmocide Ltd
Original Assignee
Pulmocide Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulmocide Ltd filed Critical Pulmocide Ltd
Publication of CN107635988A publication Critical patent/CN107635988A/zh
Application granted granted Critical
Publication of CN107635988B publication Critical patent/CN107635988B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680028971.4A 2015-05-21 2016-05-20 抗真菌的苯甲酰胺类衍生物或其可药用盐 Active CN107635988B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15168637 2015-05-21
EP15168637.5 2015-05-21
PCT/GB2016/051467 WO2016185225A1 (en) 2015-05-21 2016-05-20 Antifungal 4-(4-(4-(((3r,5r)-5-((1 h -1,2,4-triazol-1 -yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)- 3-methylphenyl)piperazin-1 -yl )-n -(2-h yd roxycyc lo h exyl) b e nzam i d e, or a pharmaceutically acceptable salt thereof.

Publications (2)

Publication Number Publication Date
CN107635988A CN107635988A (zh) 2018-01-26
CN107635988B true CN107635988B (zh) 2021-06-18

Family

ID=53267232

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680028971.4A Active CN107635988B (zh) 2015-05-21 2016-05-20 抗真菌的苯甲酰胺类衍生物或其可药用盐

Country Status (16)

Country Link
US (3) US9969720B2 (enExample)
EP (1) EP3298006B1 (enExample)
JP (1) JP6811727B2 (enExample)
KR (1) KR102653821B1 (enExample)
CN (1) CN107635988B (enExample)
AU (1) AU2016263669B2 (enExample)
CA (1) CA2981945C (enExample)
DK (1) DK3298006T3 (enExample)
EA (1) EA032454B1 (enExample)
ES (1) ES2790723T3 (enExample)
HU (1) HUE048843T2 (enExample)
IL (1) IL254943B (enExample)
MX (1) MX379586B (enExample)
NZ (1) NZ735783A (enExample)
SG (1) SG11201708007VA (enExample)
WO (1) WO2016185225A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6811727B2 (ja) * 2015-05-21 2021-01-20 プルモシデ リミテド 抗真菌性の４−（４−（４−（（（３ｒ，５ｒ）−５−（（１ｈ−１，２，４−トリアゾール−１−イル）メチル）−５−（２，４−ジフルオロフェニル）テトラヒドロフラン−３−イル）メトキシ）−３−メチルフェニル）ピペラジン−１−イル）−ｎ−（２−ヒドロキシシクロヘキシル）ベンズアミド、又はその医薬として許容し得る塩
CN109329288A (zh) * 2018-11-09 2019-02-15 青岛农业大学 伏立康唑在制备用于防治植物病原菌的杀菌剂中的应用
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5039676A (en) * 1990-05-11 1991-08-13 Schering Corporation Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
CN1142828A (zh) * 1993-12-21 1997-02-12 先灵公司 四氢呋喃抗真菌剂
CN1300287A (zh) * 1998-05-14 2001-06-20 詹森药业有限公司 用作广效性抗菌剂的水溶性唑类(一)
CN1499930A (zh) * 2001-04-03 2004-05-26 ���鹫˾ 生物利用度提高的抗真菌组合物
CN101402613A (zh) * 2008-11-14 2009-04-08 中国人民解放军第二军医大学 取代酚氧烷基胺三唑醇类抗真菌化合物及其制备方法
CN101511805A (zh) * 2006-06-22 2009-08-19 生物计划公司 作为多巴胺d3受体配体的新型羰基化(氮杂)环己烷类化合物
CN102234267A (zh) * 2010-04-21 2011-11-09 中国科学院上海药物研究所 新型三氮唑类抗真菌化合物、其药物组合物及其制备方法和用途
WO2013036866A1 (en) * 2011-09-07 2013-03-14 The Johns Hopkins University Itraconazole analogs and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1292472C (en) 1985-12-03 1991-11-26 Alfonsus Guilielmus Knaeps Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles
JPH0717634B2 (ja) * 1987-11-20 1995-03-01 シェリング・コーポレーション トリ‐およびテトラ‐置換‐オキセタンおよびテトラヒドロフランおよびその中間体
US5714490A (en) 1993-12-21 1998-02-03 Schering Corporation Tetrahydrofuran antifungals
US5486625A (en) 1994-07-08 1996-01-23 Schering Corporation Process for the preparation of chiral intermediates useful for the synthesis of antifungal agents
IL118464A (en) 1995-06-02 2000-08-13 Schering Corp (2R-cis)-4-¬4-¬4-¬4¬¬-5-(2',4 dihalophenyl)-tetrahydro-5-(1-H-1,2,4,triazol-1-yl-methyl)furan-3-yl(methoxy¾phenyl¾-1-piperazinyl¬phenyl2,4,dihydro2¬(5)-1-ethyl-2-(5)hydroxy propyl¾-3H-1,2,4-triazol-3-one and pharmaceutical compositions comprising them
HUE048905T2 (hu) 2014-12-05 2020-08-28 Pulmocide Ltd Antimikotikus vegyület
JP6811727B2 (ja) * 2015-05-21 2021-01-20 プルモシデ リミテド 抗真菌性の４−（４−（４−（（（３ｒ，５ｒ）−５−（（１ｈ−１，２，４−トリアゾール−１−イル）メチル）−５−（２，４−ジフルオロフェニル）テトラヒドロフラン−３−イル）メトキシ）−３−メチルフェニル）ピペラジン−１−イル）−ｎ−（２−ヒドロキシシクロヘキシル）ベンズアミド、又はその医薬として許容し得る塩

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5039676A (en) * 1990-05-11 1991-08-13 Schering Corporation Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
CN1142828A (zh) * 1993-12-21 1997-02-12 先灵公司 四氢呋喃抗真菌剂
CN1300287A (zh) * 1998-05-14 2001-06-20 詹森药业有限公司 用作广效性抗菌剂的水溶性唑类(一)
CN1499930A (zh) * 2001-04-03 2004-05-26 ���鹫˾ 生物利用度提高的抗真菌组合物
CN101511805A (zh) * 2006-06-22 2009-08-19 生物计划公司 作为多巴胺d3受体配体的新型羰基化(氮杂)环己烷类化合物
CN101402613A (zh) * 2008-11-14 2009-04-08 中国人民解放军第二军医大学 取代酚氧烷基胺三唑醇类抗真菌化合物及其制备方法
CN102234267A (zh) * 2010-04-21 2011-11-09 中国科学院上海药物研究所 新型三氮唑类抗真菌化合物、其药物组合物及其制备方法和用途
WO2013036866A1 (en) * 2011-09-07 2013-03-14 The Johns Hopkins University Itraconazole analogs and use thereof

Also Published As

Publication number Publication date
KR20180010189A (ko) 2018-01-30
BR112017020807A2 (pt) 2018-07-03
AU2016263669A1 (en) 2017-10-12
US20180251453A1 (en) 2018-09-06
EA032454B1 (ru) 2019-05-31
EP3298006A1 (en) 2018-03-28
EP3298006B1 (en) 2020-01-01
DK3298006T3 (da) 2020-03-30
CA2981945A1 (en) 2016-11-24
ES2790723T3 (es) 2020-10-29
US9969720B2 (en) 2018-05-15
EA201792558A1 (ru) 2018-05-31
JP2018520104A (ja) 2018-07-26
CA2981945C (en) 2023-08-29
WO2016185225A1 (en) 2016-11-24
NZ735783A (en) 2021-12-24
MX2017014814A (es) 2018-02-15
US10513511B2 (en) 2019-12-24
JP6811727B2 (ja) 2021-01-20
CN107635988A (zh) 2018-01-26
MX379586B (es) 2025-03-11
SG11201708007VA (en) 2017-12-28
US20190202813A1 (en) 2019-07-04
IL254943A0 (en) 2017-12-31
KR102653821B1 (ko) 2024-04-02
IL254943B (en) 2021-01-31
HUE048843T2 (hu) 2020-08-28
US20170114047A1 (en) 2017-04-27
HK1252779A1 (en) 2019-05-31
US10280155B2 (en) 2019-05-07
AU2016263669B2 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
US11008307B2 (en) Compounds which are used in the preparation of the compound of formula (I)
US10513511B2 (en) Aqueous suspension formulation comprising 4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluoro-phenyl)tetrahydrofuran-3-yl)methoxy)-3-methylphenyl) or a pharmaceutically acceptable salt thereof
HK40046347A (en) Antimycotic compound
HK40046347B (zh) 抗真菌的化合物
HK1252779B (en) Antifungal 4-(4-(4-(((3r,5r)-5-((1 h -1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)- 3-methylphenyl)piperazin-1-yl )-n -(2-h yd roxycyc lo h exyl) b e nzam i d e, or a pharmaceutically acceptable salt thereof
BR112017020807B1 (pt) Composto 4-(4-(4-(((3r,5r)-5-((1h-1,2,4-triazol-1-il)metil)-5-(2,4- difluorofenil)tetra-hidrofuran-3-il)metóxi)-3-metilfenil)piperazin-1-il)-n-(2- hidroxiciclo-hexil) benzamida antifúngica, seu processo de preparação, e composição farmacêutica
NZ730861B2 (en) Antimycotic compound
HK1244795B (en) Antimycotic compound

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant